Study: Age at time of Type 2 diabetes or hypertension diagnosis linked to glaucoma


Timing of type 2 diabetes or hypertension diagnosis may impact the risk of primary open-angle glaucoma.

Researchers have found that the earlier individuals develop type 2 diabetes or hypertension in life, the earlier they are likely to develop primary open-angle glaucoma (POAG).

The study’s findings were published recently in Clinical Ophthalmology,1 and could lead to better screening protocols for POAG, which accounts for up to 90% of all cases of glaucoma, the University of Texas Southwestern (UTSW) Medical Center said in a news release.2

Karanjit Kooner, MD, PhD, an associate professor of ophthalmology at UTSW, pointed out that due to the fact that POAG has few symptoms in its earliest stages, patients are frequently diagnosed in its later stages when vision has already been permanently damaged.

According to the UTSW news release, although researchers have identified several risk factors for POAG – including type 2 diabetes (T2D), hypertension (HTN), migraines, and obstructive sleep apnea (OSA) – how they might influence the onset of POAG is not well understood.

“Diabetes and hypertension have both been associated with glaucoma, but our study focused on whether the age of onset of DM or HTN was associated with the age of POAG diagnosis,” Kooner said.

According to the UTSW news release, Kooner and his colleagues collected data from the medical records of 389 POAG patients, all seen by Kooner between June 2019 and December 2019.

Researchers found that the diagnosis of T2D and HTN at an earlier age is associated with the early onset of POAG. Although the association between age at HTN diagnosis and age at POAG diagnosis (1.3% change) was significant, it was noticeably weaker than age at T2D diagnosis and age at POAG diagnosis (8.6% and 6.9% change respectively, the researchers wrote.

The UTSW news release noted that the Asian race/ethnicity was associated with earlier development of POAG for patients with T2D with or without HTN.

“Our study has unearthed an extremely important link between T2D, HTN, and glaucoma and this information should be disseminated widely for the benefit of patients and reigning in health care costs,” Kooner said in the UTSW news release. “Our data provides sufficient evidence to encourage ophthalmological examinations for patients who are diagnosed with T2D or HTN to detect early glaucoma and prevent blindness. This would be especially true for patients with a family history of glaucoma, Black race, and myopia.”

However, the researchers did not find significant contributions in predicting age at POAG diagnosis from gender, race/ethnicity, or BMI [body mass index], Kooner pointed out.

The researchers also did not find significant differences for age at POAG diagnosis based on a history of migraine or OSA, according to the news release.

“We were surprised that the age of sleep apnea or migraine diagnosis did not influence the age of POAG diagnosis,” Kooner said. “The history of migraine has been addressed previously as a possible POAG risk factor, though the relationship is still controversial.”

If the connections hold up in future research, type 2 diabetes and hypertension could be added to the list of factors that can trigger POAG screening – including a family history of POAG, elevated intraocular pressure, and Black race – and lead to earlier diagnosis of POAG, preserving patients’ vision and quality of life,’ Kooner concluded.

Kooner and colleagues plan to expand the study further in collaboration with diabetic and hypertensive clinics.


1. Wooliscroft J, Akram R, Zuberi H, et al. Predictors of early onset glaucoma. Clin Ophthalmol. 2022 Jun 10;16:1925-1932. doi: 10.2147/OPTH.S360719

2. Early onset of diabetes, hypertension can predict early glaucoma, UTSW ophthalmologists report. News release. University of Texas Southwestern Medical Center. August 29, 2022. Accessed September 6, 2022.

Recent Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
© 2024 MJH Life Sciences

All rights reserved.